Business, energy, technology, markets and global industry news from Business News Today

Affinia Therapeutics

PharmaDeviceNews Affinia Therapeutics
Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.
Pharma & Biotech

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Read More
Pharma & Biotech

What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy

Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.

Read More
FDA Fast Track for AFTX-201 raises new expectations for gene therapy in BAG3 cardiomyopathy
Pharma & Biotech

Affinia Therapeutics’ AFTX-201 Fast Track decision highlights rising interest in cardiac gene therapy

Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.

Read More